EMEA-002689-PIP02-23-M01 - paediatric investigation plan
navepegritide
PIPHuman
Key facts
- Active Substance
- navepegritide
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0275/2024
- PIP number
- EMEA-002689-PIP02-23-M01
- Pharmaceutical form(s)
- Powder and solvent for solution for injection
- Condition(s) / indication(s)
- Treatment of achondroplasia
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Ascendis Pharma Growth Disorders A/S
E-mail: medinfo@ascendispharma.com
Tel: +45 70 22 22 44- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date